Interferon‑α suppresses invasion and enhances cisplatin‑mediated apoptosis and autophagy in human osteosarcoma cells

Zhao,Jun; Wang,Mingli; Li,Zeng; Chen,Jingxian; Yin,Zongshen; Chang,Jun; Gao,Dongmei; Wang,Shiping

doi:10.3892/ol.2013.1762

Interferon‑α suppresses invasion and enhances cisplatin‑mediated apoptosis and autophagy in human osteosarcoma cells

Authors:
- Jun Zhao
- Mingli Wang
- Zeng Li
- Jingxian Chen
- Zongshen Yin
- Jun Chang
- Dongmei Gao
- Shiping Wang
View Affiliations

Affiliations: Department of Parasitology, Xiangya Medical School, Central South University, Changsha, Hunan 410078, P.R. China, Department of Microbiology, Anhui Medical University, Hefei, Anhui 230032, P.R. China, Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA, Department of Orthopedics, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230032, P.R. China , Department of Clinical Laboratory, The Third Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230032, P.R. China
Published online on: December 16, 2013 https://doi.org/10.3892/ol.2013.1762
Pages: 827-833

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Interferon (IFN)‑α is generated in response to viral infections and is used clinically in the therapy of a variety of viral infections and cancers. The present study investigated whether IFN‑α could inhibit the invasive ability of osteosarcoma cells using a Matrigel invasion assay. In addition, the osteosarcoma cells were treated with cisplatin and/or IFN‑α. Apoptosis and autophagy were assessed using 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide assay, Hoechst 33258 staining, flow cytometry assay, acridine orange staining, green fluorescent protein‑LC3 dot assay and transmission electron microscopy. Further analysis revealed that the efficacy of cisplatin was enhanced by the addition of the cytokine, IFN‑α. These results indicate that the combination therapy of chemotherapeutics and IFN‑α is a new approach for osteosarcoma, which requires validation by experiments in vivo.

View Figures

View References

1	Zhang W, Rao HY, Feng B, Liu F and Wei L: Effects of interferon-alpha treatment on the incidence of hyperglycemia in chronic hepatitis C patients: a systematic review and meta-analysis. PLoS One. 7:e392722012. View Article : Google Scholar : PubMed/NCBI
2	Tough DF: Modulation of T-cell function by type I interferon. Immunol Cell Biol. 90:492–497. 2012. View Article : Google Scholar : PubMed/NCBI
3	Yim HY, Yang Y, Lim JS, Lee MS, Zhang DE and Kim KI: The mitochondrial pathway and reactive oxygen species are critical contributors to interferon-α/β-mediated apoptosis in Ubp43-deficient hematopoietic cells. Biochem Biophys Res Commun. 423:436–440. 2012.PubMed/NCBI
4	Fishman AI, Johnson B, Alexander B, Won J, Choudhury M and Konno S: Additively enhanced antiproliferative effect of interferon combined with proanthocyanidin on bladder cancer cells. J Cancer. 3:107–112. 2012. View Article : Google Scholar
5	Harris J: Autophagy and cytokines. Cytokine. 56:140–144. 2011. View Article : Google Scholar : PubMed/NCBI
6	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
7	Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoorn PC and Egeler RM: Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer. 47:2431–2445. 2011. View Article : Google Scholar
8	Dai X, Ma W, He X and Jha RK: Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing’s sarcoma. Med Sci Monit. 17:177–190. 2011.
9	Loeb DM: Is there a role for immunotherapy in osteosarcoma? Cancer Treat Res. 152:447–457. 2009. View Article : Google Scholar : PubMed/NCBI
10	Jaffe N: Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res. 152:239–262. 2009. View Article : Google Scholar : PubMed/NCBI
11	Tarhini AA, Gogas H and Kirkwood JM: IFN-α in the treatment of melanoma. J Immunol. 189:3789–3793. 2012.
12	Pasquali S and Mocellin S: The anticancer face of interferon alpha (IFN-alpha): from biology to clinical results, with a focus on melanoma. Curr Med Chem. 17:3327–3336. 2010. View Article : Google Scholar : PubMed/NCBI
13	Moll HP, Maier T, Zommer A, Lavoie T and Brostjan C: The differential activity of interferon-α subtypes is consistent among distinct target genes and cell types. Cytokine. 53:52–59. 2011.
14	Miwa S, Kadono Y, Sugata T, Mizokami A and Namiki M: Successful treatment for metastases from renal cell carcinoma with alternation of interferon-alpha subtypes. Int J Clin Oncol. 15:97–100. 2010. View Article : Google Scholar : PubMed/NCBI
15	Mahmutović S and Beslagić E: Significance of the interferon (IFN) in the therapy. Bosn J Basic Med Sci. 4:42–44. 2004.
16	de Vries-van Leeuwen IJ, Kortekaas-Thijssen C, Nzigou Mandouckou JA, Kas S, Evidente A and de Boer AH: Fusicoccin-A selectively induces apoptosis in tumor cells after interferon-alpha priming. Cancer Lett. 293:198–206. 2010.PubMed/NCBI
17	Ota K, Matsumiya T, Sakuraba H, Imaizumi T, Yoshida H, Kawaguchi S, Fukuda S and Satoh K: Interferon-alpha2b induces p21cip1/waf1 degradation and cell proliferation in HeLa cells. Cell Cycle. 9:131–139. 2010. View Article : Google Scholar : PubMed/NCBI
18	Zhang T, Sun HC, Zhou HY, Luo JT, Zhang BL, Wang P, Wang L, Qin LX, Ren N, Ye SL, et al: Interferon alpha inhibits hepatocellular carcinoma growth through inducing apoptosis and interfering with adhesion of tumor endothelial cells. Cancer Lett. 290:204–210. 2010. View Article : Google Scholar